The SMARTEST trial is a phase II non-blinded randomized trial designed to evaluate the
benefit of low dose cyclophosphamide in sequential combination with sub-ablative radiation
(Arm A) versus sub-ablative radiation alone (Arm B) before surgery as well as the safety and
efficacy of consolidation tremelimumab-durvalumab for eligible patients after surgery in both
arms.